Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11040955 Inhibitors of (alpha-v)(beta-6) integrin

Patent 11040955 was granted and assigned to Morphic Therapeutic on June, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Morphic Therapeutic

Current Assignee

Morphic Therapeutic

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

110409550

Patent Inventor Names

Matthew G. Bursavich0

Kyle D. Konze0

Mark Brewer0

Mats A. Svensson0

Aleksey I. Gerasyuto0

Alexey A. Lugovskoy0

Blaise S. Lippa0

Bruce N. Rogers0

...

Date of Patent

June 22, 2021

Patent Application Number

164896280

Date Filed

February 27, 2018

Patent Citations

‌

US Patent 10696672 Amino acid compounds and methods of use

‌

US Patent 10604520 N-acyl amino acid compounds and methods of use

‌

US Patent 10793564 Amino acid compounds and methods of use

Patent Primary Examiner

‌

Charanjit Aulakh

Patent abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11040955 Inhibitors of (alpha-v)(beta-6) integrin

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API